MemphasysASX:MEM Gross Margin % is 50.00% as of Dec. 2025, which is 203% above its 10-year median of 16.48. The stock has 5 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Memphasys ranks worse than 99.01% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Memphasys's Gross Profit for the
six
months ended in Dec. 2025 was A$0.01 Mil. Memphasys's Revenue for the
six
months ended in Dec. 2025 was A$0.01 Mil. Therefore, Memphasys's Gross Margin % for the quarter that ended in Dec. 2025 was 50.00%.
The historical rank and industry rank for Memphasys's Gross Margin % or its related term are showing as below:
ASX:MEM'
s Gross Margin % Range Over the Past 10 Years
Min: -900 Med: 16.48 Max: 60
Current: -258.33
During the past 13 years, the highestGross Margin % of Memphasys was 60.00%. The lowest was -900.00%. And the median was 16.48%.
ASX:MEM's Gross Margin % is ranked worse than 99.01% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 52.07
vs ASX:MEM: -258.33
Memphasys had a gross margin of 50.00% for the quarter that ended in Dec. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Memphasys was 0.00% per year.
Memphasys (ASX:MEM) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Memphasys had a gross margin of 50.00% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Memphasys Gross Margin % Related Terms
Memphasys Gross Margin % Historical Data
* Premium members only.
The historical data trend for Memphasys's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:MEM vs ABT, SYK, MDT: Gross Margin % Comparison
For the Medical Devices subindustry, Memphasys's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Memphasys Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Memphasys's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Memphasys's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Memphasys (ASX:MEM) has a Gross Margin % of 50.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Memphasys and its competitors. This is 203% above median its historical median of 16.48. According to the industry distribution chart, Memphasys ranks #797 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 99%.
Is Memphasys' Gross Margin % too high?
Memphasys' current Gross Margin % of 50.00% is 203% above median its 10-year median of 16.48. The Medical Devices & Instruments industry median Gross Margin % is 52.07. Memphasys' value of 50.00% is 4% below this industry median. Based on the distribution chart, Memphasys ranks #797 out of 805 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Memphasys' Gross Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Memphasys ranks #797 out of 805 companies for Gross Margin %. This places Memphasys in the lower half of its industry. The industry median Gross Margin % is 52.07. Memphasys' value of 50.00% is 4% below this benchmark. While the company's 10-year median is 16.48 vs. the industry median of 52.07, Memphasys has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.07, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Memphasys's current Gross Margin % of 50.00% is 4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Memphasys and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Memphasys's current Gross Margin % is 50.00%, which is 203% above median its own 10-year median of 16.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Memphasys stock overvalued right now?
Memphasys (ASX:MEM) has a current Gross Margin % of 50.00%. The current Gross Margin % is 50.00%, which is 203% above median its 10-year median of 16.48 and 4% below the Medical Devices & Instruments industry median of 52.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Memphasys (ASX:MEM), the current Gross Margin % is 50.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Memphasys Ltd is an Australian reproductive biotechnology company developing and commercializing novel reproduction and fertility solutions for humans and animals. The products in its development pipeline include a range of devices, media, and in vitro diagnostic solutions. The company is currently focused on the commercialisation of its patented Felix System, a novel bio-separation technology for assisted reproduction, designed to revolutionise sperm separation in assisted reproductive technology (ART) by providing a rapid, gentle, and automated process. The group has only one operating segment, being Reproductive Technologies, the assets and liabilities of which are located in Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MEM has been successfully added to your 